World's Best Scientists 2026 revealed!
Andrés Cervantes

Andrés Cervantes

D-Index & Metrics

Medicine

D-Index
105
Citations
63972
World Ranking
6653
National Ranking
98

Andrés Cervantes publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Andrés Cervantes sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 610 publications — 73rd percentile

73% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Andrés Cervantes D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Andrés Cervantes sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 105 D-Index — 67th percentile

67% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Andrés Cervantes is affiliated with the University of Valencia in Spain and has a significant presence in the field of Medicine, particularly in Oncology. Their research contributions span a variety of subfields, including Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology, and Surgery.

The scientist's work focuses on key topics such as Cancer Genomics and Diagnostics, Colorectal Cancer Treatments and Studies, Cancer Immunotherapy and Biomarkers, Gastric Cancer Management and Outcomes, Genetic Factors in Colorectal Cancer, Colorectal Cancer Surgical Treatments, and Pancreatic and Hepatic Oncology Research.

Among their recent publications are the following papers:

  • Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2022, Annals of Oncology)
  • Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial (2020, The Lancet Oncology)
  • Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2022, Annals of Oncology)
  • Clinical management of metastatic colorectal cancer in the era of precision medicine (2022, CA A Cancer Journal for Clinicians)
  • Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver (2021, Cancer Cell)

The scientist frequently collaborates with other researchers. Their most frequent co-authors include Valentina Gambardella, Josep Tabernero, Noelia Tarazona, Susana Roselló, and Tania Fleitas.

Publication venues where they commonly publish include Annals of Oncology, ESMO Open, Journal of Clinical Oncology, Cancer Research, and Cancer Treatment Reviews.

Best Publications

  • Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer

    A. de Gramont;A. Figer;M. Seymour;M. Homerin

  • ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

    E. Van Cutsem;A. Cervantes;R. Adam;A. Sobrero

  • A phase 3 trial of bevacizumab in ovarian cancer.

    Timothy J Perren;Ann Marie Swart;Jacobus Pfisterer;Jonathan A Ledermann

  • ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

    H J Schmoll;E Van Cutsem;A Stein;V Valentini

  • Capecitabine as Adjuvant Treatment for Stage III Colon Cancer

    Chris Twelves;Alfred Wong;Marek P. Nowacki;Markus Abt

  • Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Bengt Glimelius;Lars Påhlman;A. Cervantes

  • Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    R. Labianca;B. Nordlinger;G. D. Beretta;S. Mosconi

  • Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

    Marc Peeters;Timothy Jay Price;Andrés Cervantes;Alberto F. Sobrero

  • Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    E. Van Cutsem;A. Cervantes;B. Nordlinger;D. Arnold

  • Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

    A. Okines;M. Verheij;W. Allum;D. Cunningham

  • Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.

    Renu R Bahadoer;Esmée A Dijkstra;Boudewijn van Etten;Corrie A M Marijnen;Corrie A M Marijnen

  • OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study

    Christophe Tournigand;Andres Cervantes;Arie Figer;Gérard Lledo

  • Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.

    D. Arnold;B. Lueza;J.-Y. Douillard;M. Peeters

  • Anal cancer: ESMO–ESSO–ESTRO clinical practice guidelines for diagnosis, treatment and follow-up

    Robert Glynne-Jones;Per J. Nilsson;Carlo Aschele;Vicky Goh

  • Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

    Amit M. Oza;Adrian D. Cook;Jacobus Pfisterer;Andrew Embleton

  • First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

    Josep Tabernero;Geoffrey I. Shapiro;Patricia M. LoRusso;Andres Cervantes

  • Integration of oncology and palliative care: a Lancet Oncology Commission

    Stein Kaasa;Jon Håvard Loge;Matti S. Aapro;Tit Albreht

  • Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).

    Gordon John Sampson Rustin;Ignace Vergote;Elizabeth Eisenhauer;Eric Pujade-Lauraine

  • Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up

    T. Waddell;M. Verheij;W. Allum;D. Cunningham

  • Gastric cancer: epidemiology, pathology and treatment

    S. R. Alberts;A. Cervantes;C. J. H. van de Velde

Frequent Co-Authors

Josep Tabernero
Josep Tabernero Vall d´Hebron Institute of Oncology
Bengt Glimelius
Bengt Glimelius Uppsala University
Fortunato Ciardiello
Fortunato Ciardiello University of Campania "Luigi Vanvitelli"
Michel Ducreux
Michel Ducreux Institut Gustave Roussy
David Cunningham
David Cunningham Royal Marsden NHS Foundation Trust
José Baselga
José Baselga Memorial Sloan Kettering Cancer Center
Gina Brown
Gina Brown Imperial College London
Thierry André
Thierry André Université Paris Cité
Ian Chau
Ian Chau Royal Marsden NHS Foundation Trust

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online degree options in medicine and healthcare reveals a growing demand for flexible and accelerated programs. Many students seek ways to advance their careers quickly, which is why the fastest msn to dnp program is an attractive option. These programs allow registered nurses to move efficiently into higher-level clinical and leadership roles.

Affordability is another key consideration. If cost is a concern, there are many affordable dnp programs available online that provide quality education without excessive debt. For those eager to begin working quickly, a fast track medical lpn program can be a strategic start, leading to entry-level positions in healthcare in less time.

Specialization also matters. The shortest post master's pmhnp online programs offer a focused pathway for those wanting to serve in psychiatric mental health, addressing the growing need for mental health professionals. These online career pathways provide flexible, accessible opportunities for advancement in medicine.

Best Scientists Citing Andrés Cervantes

Trending Scientists

Recently Published Articles